Unmet Needs and Future Directions for GPRC5D Bispecific Therapy

A real-world study assessed treatment patterns and outcomes of elderly patients with lenalidomide-refractory multiple myeloma after 1 to 3 therapy lines.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

The absence of a PFS and OS benefit in the transplant arm was consistent across key subgroups in the phase 3 GMMG ReLApsE trial.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Data highlight a need for randomized clinical trials to compare the efficacy and safety of VRD vs VTD in transplant-eligible multiple myeloma.

Despite prior relapses, 200 mg of linvoseltamab elicited complete responses or better in 49.6% of patients with relapsed/refractory multiple myeloma.